These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2398 related articles for article (PubMed ID: 32076145)

  • 1. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease.
    Lavelle A; Sokol H
    Nat Rev Gastroenterol Hepatol; 2020 Apr; 17(4):223-237. PubMed ID: 32076145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of metabolites derived from gut microbiota in inflammatory bowel disease.
    Zheng L; Wen XL; Duan SL
    World J Clin Cases; 2022 Mar; 10(9):2660-2677. PubMed ID: 35434116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastro-intestinal tract: The leading role of mucosal immunity.
    Steinert A; Radulovic K; Niess J
    Swiss Med Wkly; 2016; 146():w14293. PubMed ID: 27045424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Microbial Metabolites on Microbiota-Gut-Brain Axis in Inflammatory Bowel Disease.
    Banfi D; Moro E; Bosi A; Bistoletti M; Cerantola S; Crema F; Maggi F; Giron MC; Giaroni C; Baj A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Bacterial Metabolites on Gut Barrier Function and Host Immunity: A Focus on Bacterial Metabolism and Its Relevance for Intestinal Inflammation.
    Gasaly N; de Vos P; Hermoso MA
    Front Immunol; 2021; 12():658354. PubMed ID: 34122415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disturbances of the Gut Microbiota and Microbiota-Derived Metabolites in Inflammatory Bowel Disease.
    Hu Y; Chen Z; Xu C; Kan S; Chen D
    Nutrients; 2022 Dec; 14(23):. PubMed ID: 36501169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota-derived metabolites as central regulators in metabolic disorders.
    Agus A; Clément K; Sokol H
    Gut; 2021 Jun; 70(6):1174-1182. PubMed ID: 33272977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota in the pathogenesis of inflammatory bowel disease.
    Nishida A; Inoue R; Inatomi O; Bamba S; Naito Y; Andoh A
    Clin J Gastroenterol; 2018 Feb; 11(1):1-10. PubMed ID: 29285689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis.
    Pan Y; Zhang H; Li M; He T; Guo S; Zhu L; Tan J; Wang B
    Gut Microbes; 2024; 16(1):2356284. PubMed ID: 38769683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases.
    Vich Vila A; Zhang J; Liu M; Faber KN; Weersma RK
    Gut; 2024 Oct; 73(11):1909-1920. PubMed ID: 39002973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bile Acid-Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside.
    Yang M; Gu Y; Li L; Liu T; Song X; Sun Y; Cao X; Wang B; Jiang K; Cao H
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
    Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
    J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbial Metabolites Determine Host Health and the Status of Some Diseases.
    Sittipo P; Shim JW; Lee YK
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31653062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of intestinal microbiota and metabolites in inflammatory bowel disease.
    Dong LN; Wang M; Guo J; Wang JP
    Chin Med J (Engl); 2019 Jul; 132(13):1610-1614. PubMed ID: 31090547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease.
    Li L; Liu T; Gu Y; Wang X; Xie R; Sun Y; Wang B; Cao H
    Front Immunol; 2022; 13():974305. PubMed ID: 36211363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in gut Microbiota mediated therapeutic targets in inflammatory bowel diseases: Emerging modalities for future pharmacological implications.
    Shamoon M; Martin NM; O'Brien CL
    Pharmacol Res; 2019 Oct; 148():104344. PubMed ID: 31400403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Microbiota and inflammatory bowel disease: an update.].
    De Sire R; Talocco C; Petito V; Lopetuso LR; Graziani C; Gasbarrini A; Scaldaferri F
    Recenti Prog Med; 2018 Dec; 109(12):570-573. PubMed ID: 30667386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiome in primary sclerosing cholangitis: A review.
    Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
    World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Gastrointestinal Immunity by Metabolites.
    Gu BH; Kim M; Yun CH
    Nutrients; 2021 Jan; 13(1):. PubMed ID: 33430497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Gut Microbiota in Inflammatory Bowel Disease.
    Sheehan D; Shanahan F
    Gastroenterol Clin North Am; 2017 Mar; 46(1):143-154. PubMed ID: 28164847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 120.